| Autor: |
P. Balamanikandan, M. Anusuya, R. Sharmila Dev, S. Sunil Kumar, B. Priyanka, Bermio. V.S. |
| Rok vydání: |
2022 |
| Zdroj: |
INDIAN JOURNAL OF APPLIED RESEARCH. :11-14 |
| DOI: |
10.36106/ijar/1700437 |
| Popis: |
Background:A surge of mucormycosis during the second wave of COVID intrigued the doctors in India to look for the epidemiology of the illness.Diabetes is the most common risk factor for mucormycosis.COVID can cause hyperglycemia due to various reasons.In this study,we describe the outcome of post COVID mucormycosis with respect to the glycemic status of the patient. (1)To describe the glycemic parameters of patients with COVID-19 Associated M Objectives: ucormycosis.(2)To describe the one month outcome of the patients.(3)To compare patients with Newly Diagnosed Diabetes Mellitus Post COVID-19 and patients having preexisting diabetes mellitus. 75 patients with probable or proven mucormycosis wit Methodology: h history of COVID atleast 2 weeks before were randomly selected from the mucor ward of Rajiv Gandhi Government General Hospital and their glycemic prole assessed.They were followed up for one month and the results were statistically analyzed. Regarding the prior CO Results: VID illness,patients had a median hospital stay of 7 days,received 5 days of intravenous steroids and 3.48 days of supplemental oxygen.Patients who had hyperglycemia during COVID also had statistically signicantly higher iv steroid use and higher need for oxygen.There was a statistically very signicant(p |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
